PL2219451T3 - Sposób leczenia nowotworów tkanek krwiotwórczych - Google Patents

Sposób leczenia nowotworów tkanek krwiotwórczych

Info

Publication number
PL2219451T3
PL2219451T3 PL08851754T PL08851754T PL2219451T3 PL 2219451 T3 PL2219451 T3 PL 2219451T3 PL 08851754 T PL08851754 T PL 08851754T PL 08851754 T PL08851754 T PL 08851754T PL 2219451 T3 PL2219451 T3 PL 2219451T3
Authority
PL
Poland
Prior art keywords
hematopoietic neoplasms
treating hematopoietic
treating
neoplasms
hematopoietic
Prior art date
Application number
PL08851754T
Other languages
English (en)
Inventor
David Chaplin
Bronwyn G Siim
Original Assignee
Oxigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc filed Critical Oxigene Inc
Publication of PL2219451T3 publication Critical patent/PL2219451T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL08851754T 2007-11-21 2008-11-21 Sposób leczenia nowotworów tkanek krwiotwórczych PL2219451T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98978607P 2007-11-21 2007-11-21
PCT/US2008/084427 WO2009067706A1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms
EP08851754.5A EP2219451B1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms

Publications (1)

Publication Number Publication Date
PL2219451T3 true PL2219451T3 (pl) 2015-04-30

Family

ID=40667883

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08851754T PL2219451T3 (pl) 2007-11-21 2008-11-21 Sposób leczenia nowotworów tkanek krwiotwórczych

Country Status (12)

Country Link
US (4) US20090264382A1 (pl)
EP (1) EP2219451B1 (pl)
JP (1) JP5302328B2 (pl)
AU (1) AU2008326251B2 (pl)
CA (1) CA2703283C (pl)
DK (1) DK2219451T3 (pl)
ES (1) ES2529434T3 (pl)
HR (1) HRP20150040T1 (pl)
PL (1) PL2219451T3 (pl)
PT (1) PT2219451E (pl)
SI (1) SI2219451T1 (pl)
WO (1) WO2009067706A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481249A1 (en) * 2002-03-07 2004-12-01 Cambridge University Technical Services Limited Scd fingerprints
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US11478445B2 (en) * 2017-10-25 2022-10-25 Bionomics Ltd. Method for treating acute myeloid leukemia
CA3126163A1 (en) * 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
EP1003498A4 (en) 1997-03-26 2004-07-14 Biosource Tech Inc DIAYLETHER AND THEIR DERIVATIVES LIKE ANTI-CANCER COMPOUNDS
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1045853B1 (en) 1998-01-09 2010-08-04 ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY Synthesis of combretastatin a-4 prodrugs
WO1999034788A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US6433012B1 (en) 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
JP2002507567A (ja) 1998-03-25 2002-03-12 ラージ スケール バイオロジー コーポレイション 血管形成を阻害するための安息香酸誘導体
WO1999051246A1 (en) 1998-04-03 1999-10-14 Ajinomoto Co., Inc. Antitumor agents
WO2000006556A1 (en) 1998-07-27 2000-02-10 Abbott Laboratories Substituted oxazolines as antiproliferative agents
AU2190700A (en) 1998-12-17 2000-07-03 Tularik Inc. Tubulin-binding agents
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
CO5170498A1 (es) 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US6201001B1 (en) 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
CA2407967C (en) * 2000-03-10 2010-10-05 Baylor University Tubulin binding ligands and corresponding prodrug constructs
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
ATE527271T1 (de) 2000-04-27 2011-10-15 Univ Arizona Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat
WO2001081288A1 (en) 2000-04-27 2001-11-01 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Hydroxyphenstatin and the prodrugs thereof
US20040122083A1 (en) 2000-05-09 2004-06-24 Pettit George R Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
AU2001261474B2 (en) * 2000-05-15 2006-03-09 Celgene Corporation Compositions and methods for the treatment of cancer
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU2001296215A1 (en) * 2000-07-17 2002-01-30 Oxi-Gene, Inc. Efficient method of synthesizing combretastatin a-4 prodrugs
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
EP1351912A2 (en) 2000-12-21 2003-10-15 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
AU2002246827B2 (en) * 2000-12-22 2008-02-21 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
GB2377469B (en) 2001-07-13 2005-07-06 Prismo Ltd Method and apparatus for laying a traffic calming surface
EP1438281A4 (en) 2001-10-26 2006-04-26 Oxigene Inc FUNCTIONALIZED STILBENE DERIVATIVES USEFUL AS IMPROVED VASCULAR TARGETING AGENTS
GB0126889D0 (en) 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
US7105695B2 (en) 2001-12-21 2006-09-12 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of combretastatin A-2 prodrugs
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040024696A1 (en) 2002-08-02 2004-02-05 Federico Alves System for automatically transferring funds
TW549690U (en) 2002-11-13 2003-08-21 Tekcon Electronics Corp Electrical card connector
EP1601348A4 (en) 2003-02-28 2008-12-10 Oxigene Inc Compositions and methods with improved therapeutic activity
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms

Also Published As

Publication number Publication date
CA2703283C (en) 2016-01-12
US20090192098A1 (en) 2009-07-30
JP2011504510A (ja) 2011-02-10
CA2703283A1 (en) 2009-05-28
JP5302328B2 (ja) 2013-10-02
HRP20150040T1 (hr) 2015-02-27
PT2219451E (pt) 2015-02-09
AU2008326251B2 (en) 2014-03-06
EP2219451B1 (en) 2014-11-12
DK2219451T3 (en) 2015-01-12
EP2219451A1 (en) 2010-08-25
US20090264382A1 (en) 2009-10-22
AU2008326251A1 (en) 2009-05-28
US20120270831A1 (en) 2012-10-25
SI2219451T1 (sl) 2015-02-27
EP2219451A4 (en) 2011-01-19
ES2529434T3 (es) 2015-02-20
WO2009067706A1 (en) 2009-05-28
US9040500B2 (en) 2015-05-26
US20150246064A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL209895A0 (en) Compounds for treating beta-amyloidoses
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
ZA201001753B (en) Method for consumer-dispenser interactions
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
PL2361116T3 (pl) Urządzenie do naświetlania
PL2376410T3 (pl) Sposób suszenia
IL209894A0 (en) Compounds for treating amyloidoses
PL2376597T3 (pl) Proces obróbki odpadów
GB0803107D0 (en) Method
IL213476A0 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
PL2301893T3 (pl) Sposób oczyszczania ścieku
IL208069A0 (en) Methods for treating psoriasis
IL213398A0 (en) Compounds for treating cancer
IL210097A0 (en) Compositions and methods for treating unfluenza
GB0810566D0 (en) Co-existence method
IL199739A0 (en) Methods for treating psoriasis
GB0804981D0 (en) Method
GB0804690D0 (en) Method
GB0807409D0 (en) Method
IL212212A0 (en) Compound useful for treating cellulite
EP2251078A4 (en) POWDER TREATMENT DEVICE
GB0807410D0 (en) Method
SI2219451T1 (sl) Postopek za zdravljenje hematopoetskih neoplazem
EP2144888A4 (en) METHODS OF TREATING CANCER